Institut für Allgemeinmedizin



Procurement of vaccination as an obstacle to vaccination in Germany

Poster: 6th Northern European Conference on Travel Medicine, 01.-04. June 2016, London, United Kingdom

Autoren/Herausgeber: Lukas Englert
Linda Sanftenberg
Hans-Jürgen Schrörs
Jörg Schelling
Erschienen: 2016

Aims/ objectives: Until now, the vaccination rates in Germany are far too low, to reach the eradication of different infectious diseases like measles, rubella, varicella or herpes zoster. Within our study on obstacles to vaccination (OV), we compared different aspects which could prevent resident physicians from high vaccination rates. Methods: To assess the relevance of 17 different OVs, we sent the invitation to our online-survey to resident physicians (general practitioners, gynecologists and pediatricians). These 17 OVs were identified via a systematic literature review and a paper based questionnaire which was sent before to the Associations of Statutory Health Insurance Physicians (ASHIP), professional associations of resident physicians, pharmaceutical companies and associations of health insurance companies. Results: There are only two vaccine suppliers which produce the full range of basic vaccines recommended by the Robert-Koch-Institut (RKI). This monopolization leads to procurement problems of vaccines and a declining number of monovalent vaccines. Accordingly, in January 2016 the Paul-Ehrlich-Institut (PEI) registered 15 different vaccines with either procurement problems that last longer than two weeks or the producers cannot comply with an increased demand.In our online-survey 252 (54%) resident physicians considered procurement problems of vaccines to be relevant. In Germany there are no monovalent vaccines for rubella, mumps, diphteria, Haemophilus influenzae type B or pertussis. 439 (95%) resident physicians feel the need for monovalent vaccines and 218 (47%) perceive it as a relevant OV. Conclusion:There is only a limited number of vaccines suppliers, so sudden demand of vaccines like an epidemic outbreak leads to a strained situation in vaccine procurement. Politics and pharmaceutical companies must work together to stop monopolization and to ensure constant and adequate quantity of combined and monovalent vaccines to reach high vaccination rates.